GTN Oversight: A New Standard of Transparency Is Here

The shift to GTN oversight is already underway. In this webinar, we’ll explore why claims collection across all 340B purchases is becoming the foundation for greater transparency across the drug discount landscape, what manufacturers can learn when they unlock claims-level visibility across all 340B utilization, and why the market is moving in this direction now after years of fragmented progress.

Key topics include:

How claims-level data supports stronger oversight, transparency, and financial control across the GTN ecosystem
The new insights manufacturers can uncover when they gain visibility into all 340B utilization
Why the industry is accelerating toward comprehensive claims collection and broader GTN oversight
The risks and limitations of managing 340B and other pricing programs in isolation
How claims-level visibility can help identify revenue leakage, improve decision-making, and support future program readiness

Speaker:

Dan Golder, Product Director at Kalderos

Register Today

Provide your details to attend.

Lorem ipsum dolor sit, amet consectetur adipisicing elit. Excepturi adipisci iure ipsam dicta mollitia illum! Atque nostrum assumenda distinctio enim ipsam aliquam veniam incidunt explicabo, quae nemo id voluptatum magni.